Lamzede
velmanase alfa · Chiesi Farmaceutici S.p.A.
ORPHAN EXCEPTIONAL CIRCUMSTANCES AUTHORISED IN THE EUWhat Lamzede is used for
Treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Lamzede
- Active substance
- velmanase alfa
- Disease area
- alpha-Mannosidosis
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB15
- Marketing authorisation holder
- Chiesi Farmaceutici S.p.A.
- Authorised in the EU since
- 2018
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lamzede used for?
Treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
What is the active substance in Lamzede?
Lamzede contains velmanase alfa.
Who makes Lamzede?
The EU marketing authorisation holder is Chiesi Farmaceutici S.p.A..
Is Lamzede an orphan medicine?
Yes. Lamzede is designated an orphan medicine in the EU, for a rare disease (alpha-Mannosidosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU